Navigation Links
Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
Date:6/2/2010

p>This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
2. Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
3. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
4. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... CA (PRWEB) April 30, 2015 Cytokinetics, Incorporated ... first quarter of 2015 were $4.4 million, compared to $8.0 ... loss for the first quarter was $8.9 million, or $0.23 ... net loss for the same period in 2014, of $8.7 ... of March 31, 2015, cash, cash equivalents and investments totaled ...
(Date:4/30/2015)... April 30, 2015 Oxford Finance LLC ("Oxford"), ... life sciences and healthcare services companies, today announced the ... agreement with Celula, Inc., a diagnostic testing company focused ... better patient care and improved outcomes.  Proceeds of the ... expand the commercialization of its products in the U.S. ...
(Date:4/30/2015)... , April 30, 2015  The Paul G. Allen ... Investigator (ADI) grants to six groups of researchers with ... challenging roadblocks in neuroscience: growing mature human brain cells ... total of $7.5 million over three years.  ... their research is especially significant because the field of ...
(Date:4/30/2015)... April 30, 2015 - ... Biotechnology Company   Shire (LSE: SHP, ... three months to March 31, 2015. ... million +9% +13% Total revenues $1,488 million +11% +15% ... GAAP operating income from continuing operations $475 million +55% ...
Breaking Biology Technology:Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Oxford Finance Provides $10 Million Debt Financing to Celula 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24
... Genetics, the parent company of Myeloma Health, a privately ... announced the formation of their Scientific Advisory Board. They ... Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer ... Medical School Dr. Anderson of Dana-Farber Cancer ...
... AutoGenomics, a leader in providing automated, molecular testing solutions ... the U.S. Food and Drug Administration to market its ... *2, *3, *17, of the CYP450 2C19 gene and ... testing platform, the INFINITI® Analyzer.   "We ...
... ("China-Biotics", the "Company") (Nasdaq: CHBT ), the ... China, today announced it will host a conference call ... Beijing Time on Tuesday, November 9, 2010, to discuss ... financial results for the period ended September 30, 2010. ...
Cached Biology Technology:Signal Genetics Announces Establishment of Scientific Advisory Board 2Signal Genetics Announces Establishment of Scientific Advisory Board 3AutoGenomics Receives FDA Clearance for its INFINITIĀ® CYP2C19 Assay 2China-Biotics to Report Fiscal Year 2011 Second Quarter Financial Results on November 9 2
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... Science Research Conference on focuses on recent advances in ... transcriptional regulators, currently numbering 17, and will also include ... Held twice previously, this FASEB Conference is the ... The major themes of the conference will be the ...
... medicine? The media are invited to register now for ... Clinical Genetics Meeting, March 25-29, 2014 at the Nashville ... Sequencing to Cancer Genetics, the focus of the ACMG ... genomics in healthcare, showcasing the latest breakthroughs in genetics ...
... European consortium of epilepsy researchers has reported the discovery ... Using a novel combination of technologies, including trio exome ... tiny larvae of zebrafish, the EuroEPINOMICS RES consortium found ... a subset of epilepsy patients with symptoms similar to ...
Cached Biology News:Complimentary press registration now open for ACMG 2014 Annual Clinical Genetics Meeting 2European epilepsy consortium identifies new gene for severe childhood epilepsy 2European epilepsy consortium identifies new gene for severe childhood epilepsy 3European epilepsy consortium identifies new gene for severe childhood epilepsy 4
Polyclonal Antibody to PRG3...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Mouse monoclonal [2991] to C3a / C3a des Arg ( Abpromise for all tested applications). SwissProtID: P01024...
Polyclonal Antibody to SHPRH...
Biology Products: